Dr. Jiawen Xu presents AsymBio’s AmigoCHO™ platform and "CLD toolbox" strategies designed to accelerate cell line development and overcome CMC bottlenecks for complex antibody and ADC programs.

The ADC pipeline and advanced antibody modalities are expanding rapidly, putting greater challenges on upstream timelines. Establishing a robust, high-performing cell line early is increasingly critical to keeping CMC on track and enabling downstream success. In this webinar, Dr. Jiawen Xu outlines AsymBio’s integrated, multi-site capabilities supporting antibody and ADC programs, introduce the AmigoCHO™ cell line development (CLD) platform, and share practical “CLD toolbox” strategies for common development bottlenecks. The session concludes with case studies that highlight the philosophy of AysmBio on empowering global clients: Do the right things the first time, and do them in right ways.

Key Topics Include:

  • Understand AsymBio’s capabilities as a partner for antibody and ADC development
  • Learn how the AmigoCHO™ CLD platform is applied in a standardized CLD workflow
  • Identify CLD bottlenecks and toolbox strategies used to facilitate clone screening
  • Take away practical lessons to increase your chances of success in CLD

Presenters

Jiawen Xu, ;PhD

Jiawen Xu, PhD

Senior Director
Cell Line Development & Center of Biological Technology and Innovation
AsymBio

Dr. Jiawen Xu has over 10 years of experience in the CDMO industry, focusing on cell line development (CLD), cell culture development, and technology development for biologics programs.
Watch Webinar

Webinar Host

AsymBio

AsymBio is a technology-driven global CDMO specializing in biologics, bioconjugates (ADCs, AOCs, PDCs, RDCs), antibodies and recombinant proteins. We deliver comprehensive end-to-end CDMO services from early-stage R&D to commercial-scale manufacturing, backed by GMP-compliant facilities meeting US, EU and China standards.

VIEW PROFILE
AsymBio

Additional Content From AsymBio

ADC Payload-Linker CMC Process Development Strategy

ADC Payload-Linker CMC Process Development Strategy

Hear Dr. Zheng Wei share a comprehensive payload-linker CMC development strategy that covers regulatory guidance, RSM selection, and stage-appropriate quality control to navigate the evolving complexities of ADC design from IND to NDA.

Related Content